Cephalon

Last updated

Cephalon, Inc.
Subsidiary of Teva Pharmaceutical Industries
ISIN US1567081096  OOjs UI icon edit-ltr-progressive.svg
Industry Biotechnology, Biopharmaceutical
Founded1987;33 years ago (1987)
Founder
Headquarters Frazer, Pennsylvania [ citation needed ]
Key people
J. Kevin Buchi, CEO[ when? ][ citation needed ]
Productsalertness drug Provigil, the painkiller Actiq, seizure medication Gabitril [1]
Number of employees
3,726 (December 31, 2010)[ citation needed ]
Parent Teva Pharmaceutical Industries   OOjs UI icon edit-ltr-progressive.svg
Website www.cephalon.com

Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., [1] neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with the DuPont Company.[ not verified in body ] Baldino served as Cephalon's chairman and chief executive officer,[ not verified in body ] until his death in December 2010. [1] The company's name comes from the adjective "cephalic" meaning "related to the head or brain", as it was established primarily to pursue treatments for neurodegenerative diseases.[ not verified in body ]

Contents

As noted by fundinguniverse.com, in its early years,

"Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms." [2]

Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006.[ not verified in body ] Sales revenues reached $2.8 billion in 2010,[ not verified in body ] ranking Cephalon among the leading biopharmaceutical companies in the world at that time.[ not verified in body ]

On May 2, 2011, Teva Pharmaceutical Industries announced it would acquire Cephalon; [3] [ better source needed ] as of this date,[ when? ] the deal had closed, making Cephalon a subsidiary of Teva.[ not verified in body ][ needs update ]

Product development and aquisition history

The company's early research efforts were focused on the development of IGF-1, an insulin-like growth factor, in collaboration with Chiron Corporation, toward the development of a treatment for amyotrophic lateral sclerosis (Lou Gehrig's Disease), a candidate that was never approved.[ citation needed ]

Thereafter, the company developed and commercialized products for the treatment of sleep disorders, pain, [1] addiction and cancer,[ citation needed ] establishing the "wake franchise"[ This quote needs a citation ] on the basis of Provigil (modafinil) and later, Nuvigil, the R-enantiomer of modafinil.[ citation needed ] In addition to conducting research on kinase inhibitors and other small molecules,[ citation needed ] Cephalon licensed other compounds, purchased other products, and acquired entire companies, in the latter case, including CIMA Labs, Anesta, and Laboratoire Lafon.[ citation needed ] It was from Lafon that Cephalon obtained the rights to modafinil, which it marketed under the trade name Provigil, for the treatment of excessive daytime sleepiness associated with narcolepsy, sleep apnea, and shift work sleep disorder.[ citation needed ] Sales of Provigil reached nearly one billion dollars in 2008.[ citation needed ]

In February 2009, Cephalon acquired the Australian biotechnology firm, Arana Therapeutics, which brought Cephalon its lead biologic candidate, ART621, a candidate for inflammatory diseases,[ citation needed ] and biologics for the treatment of cancers.[ verification needed ][ citation needed ] Then, as infogrok.com noted in February 2010, "Cephalon... exercised its option to acquire Ception Therapeutics, following receipt of positive data from a clinical study in adults with eosinophilic asthma." [4] [ better source needed ] Commenting on this, Frank Baldino Jr., CEO of Cephalon, said, “The acquisition of Ception is consistent with our strategy to diversify into biologics and provides us with an important phase three asset for further development.” [4] [ better source needed ]

At the time of Baldino's death in 2010, the company he had co-founded in 1987 was best known for the alertness drug Provigil, the painkiller Actiq, and the seizure disorder medication Gabitril. [1] In 2011, Cephalon agreed to acquire ChemGenex Pharmaceuticals, which would provided Cephalon with marketing rights to Omapro, a therapeutic agent for a drug-resistant leukemia, in the oncology therapeutic area. [5]

Management and locations

Longtime chief financial officer J. Kevin Buchi succeeded Baldino as CEO in 2011.[ citation needed ] Members of the board included:[ when? ] venture capitalist William Egan, former COR Therapeutics CEO Vaughan Kailian, prominent healthcare economist Dr. Gail Wilensky, former SmithKline Beecham executive Dr. Martyn Greenacre, former Harvard physician and Glaxo USA head Dr. Charles Sanders and former Ambassador Kevin Moley.[ citation needed ]

The company was headquartered west of Philadelphia, in Frazer, Pennsylvania, and had research operations in nearby West Chester and manufacturing and other operations in suburban Minneapolis, Minnesota and Salt Lake City, Utah.[ citation needed ] European operations were based near Paris, France.[ citation needed ] After the acquisition of Arana,[ when? ] Research and Development operations continued in Sydney, Australia.[ citation needed ]

In 1999 Cephalon settled a lawsuit for $17 million in which it had faced claims that Baldino and other company executives had overstated the potential for a drug aimed at treating amyotrophic lateral sclerosis (Lou Gehrig's disease). [6] In addition, the Federal Trade Commission filed suit against Cephalon,[ when? ] stating that it had made "illegal deals with generic drug companies to delay generic competition to Provigil", an accusation that Cephalon has reportedly disputed. [1] [ needs update ] In September 2008, Cephalon paid $425 million to the federal government to settle four whistleblower lawsuits and a criminal charge alleging Cephalon had marketed Actiq, Gabitril and Provigil for “off-label” (unapproved) uses. [7] [ better source needed ]

Products

Select products that Cephalon manufactured and marketed included:[ when? ][ citation needed ]

Related Research Articles

Modafinil Medication which increases wakefulness

Modafinil, sold under the brand name Provigil among others, is a medication to treat sleepiness due to narcolepsy, shift work sleep disorder, or obstructive sleep apnea. While it has seen off-label use as a purported cognitive enhancer, the research on its effectiveness for this use is not conclusive. It is taken by mouth.

Adrafinil pharmaceutical drug

Adrafinil is a eugeroic that was formerly used in France to promote alertness, attention, wakefulness, positive mood, and other parameters, particularly in the elderly. It was also used off-label by individuals who wished to avoid fatigue, such as night workers or others who needed to stay awake and alert for long periods of time. Additionally, "adrafinil is known to a larger nonscientific audience, where it is considered to be a nootropic agent."

Barr Pharmaceuticals company

Barr Pharmaceuticals was a global specialty and generic drug manufacturer with operations in 30 countries.

Dr. Reddy's Laboratories is a multinational pharmaceutical company. The company was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology product

Tiagabine chemical compound

Tiagabine is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders and panic disorder.

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health, and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products.

Boehringer Ingelheim German pharmaceutical company

C.H. Boehringer Sohn AG & Ko. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

Armodafinil Drug enhancing wakefulness

Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil). It consists of only the (R)-(−)-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. and was approved by the U.S. Food and Drug Administration (FDA) in June 2007. In 2016, the FDA granted Mylan rights for the first generic version of Cephalon's Nuvigil to be marketed in the U.S.

Ipsen is a French pharmaceutical company headquartered in Paris, France.

Teva Pharmaceutical Industries Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is a multinational pharmaceutical company with dual headquarters in Petah Tikva, Israel (global) and Parsippany, New Jersey, U.S. (commercial). It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.

European Federation of Pharmaceutical Industries and Associations

The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association founded in 1978 representing the research-based pharmaceutical industry operating in Europe.

Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.

Lestaurtinib chemical compound

Lestaurtinib is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), tropomyosin receptor kinase (trk) A (TrkA), TrkB and TrkC.

WuXi AppTec Group is a global pharmaceutical, biopharmaceutical, and medical device company.

Frank Baldino Jr. was an American pharmacologist and scientist who was one of the co-founders of the pharmaceutical firm Cephalon, a company that was formed in 1987 and had grown to annual sales of $2.8 billion and net income of $425 million in 2010.

Cubist Pharmaceuticals

Cubist Pharmaceuticals is an American biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA.

Teva api is an international pharmaceutical company headquartered in Israel. teva api is a stand-alone business unit of Teva Pharmaceutical Industries limited, the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.

Horizon Therapeutics plc is an Irish–tax registered pharmaceutical company that acquires, rebrands, repackages, and reprices specialist drugs for sale into the U.S. healthcare system, which represented 97% of Horizon's 2017 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019 shareholders of the company approved the change of the company's name to Horizon Therapeutics plc.

Allergan plc is an Irish-domiciled pharmaceutical company that acquires, develops, and markets brand name drugs, and in 2017 generated 80% net sales from the U.S. healthcare system. Allergan plc was formed in February 2015 when Irish–registered Actavis plc acquired U.S.–registered Allergan, Inc., and assumed the Allergan name. Actavis was a 2013 U.S. tax inversion that moved its legal domicile to Ireland to avoid U.S. taxes. Actavis used the Irish low-tax corporate system to acquire large U.S. pharmaceutical firms, and redomicile them to Ireland.

References

  1. 1 2 3 4 5 6 7 Meier, Barry (December 21, 2010). "Frank Baldino Jr., Founder of Pharmaceutical Company, Dies at 57" . The New York Times. Retrieved November 21, 2018.
  2. Funding Universe Staff (November 30, 2015). "History of Cephalon, Inc". FundingUniverse.com. Retrieved November 30, 2015. As a small research house, Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.
  3. Teva Staff (May 1, 2011). "טבע רוכשת את Cephalon תמורת 6.8 מיליארד דולר [Teva acquires Cephalon for $ 6.8 billion]" (press release). Teva.co.il. Retrieved February 10, 2020.[ better source needed ]
  4. 1 2 Staff Writer (February 24, 2010). "Cephalon To Acquire Ception Therapeutics". Archived from the original on February 27, 2010. Retrieved February 10, 2020.
  5. Bennett, Simeon (March 29, 2011), "Cephalon agrees to acquire ChemGenex: Potential leukemia drug key to $230M purchase", Delaware Online, Bloomberg News, retrieved March 30, 2011
  6. "Westlaw Sign In | Thomson Reuters". signon.thomsonreuters.com. Retrieved February 21, 2020.
  7. Phillips and Cohen Staff (July 8, 2019) [September 29, 2008]. "Cephalon Pays $425M to Settle Whistleblower Off-label Marketing Case: Whistleblower Bruce Boise–Cephalon opioid lollipops lawsuit" (press release). Washington, D.C.: Phillips & Cohen LLP. Retrieved February 10, 2020.[ better source needed ]